Is LRMR or LXRX more undervalued in 2026?

CirclFi compares Larimar Therapeutics, Inc. (LRMR) and Lexicon Pharmaceuticals, Inc. (LXRX) using 13 institutional-grade valuation models. LRMR has a Quality of Company score of 4.8/10 while LXRX scores 7.4/10.

Which is a better buy — LRMR or LXRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do LRMR and LXRX valuations compare?

LRMR at $3.48 and LXRX at $2.18 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

LRMR vs LXRX Valuation Comparison 2026 — Intrinsic Value Analysis

LRMR

Pharmaceutical Preparations

Larimar Therapeutics, Inc.

Quality

4.8

out of 10

Value Trap

LOW

Price

$3.48

Last close

Models

7/13

Active

LXRX

Pharmaceutical Preparations

Lexicon Pharmaceuticals, Inc.

Quality

7.4

out of 10

Value Trap

SAFE

Price

$2.18

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	LRMR Fair Value	LRMR Upside	LXRX Fair Value	LXRX Upside
Bayesian DCF	Intrinsic	$1.86	-46.6%	$0.59	-72.8%
Earnings Power Value	Intrinsic	—	—	$0.29	-81.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.82	-47.6%	$0.18	-91.9%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for LRMR vs LXRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LRMR vs LXRX — Which Stock Is More Undervalued?

LXRX scores higher with a 7.4/10 quality rating vs LRMR's 4.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Larimar Therapeutics, Inc. (LRMR) and Lexicon Pharmaceuticals, Inc. (LXRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LRMR currently trades at $3.48 with a QOC of 4.8/10, while LXRX trades at $2.18 with a QOC of 7.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).